Securities Litigation and Life Sciences: A Review of the Risks Facing Manufacturers of FDA-Regulated Drugs and Medical Devices

Life sciences companies, including drug and medical device manufacturers, are frequent targets in securities class action lawsuits. These companies depend on FDA clearance or approval to manufacture and market their products, and public disclosures during the regulatory process can provide fertile ground for scrutiny by plaintiffs’ firms in the event of an adverse post-market study outcome, labeling change or other negative event. Recent years have shown a growing trend of such lawsuits.

Join our experienced securities litigators for a discussion of these issues, including the risks facing drug and medical device manufacturers in securities litigation and best practices during pre-market product development and post-market distribution for minimizing these litigation risks.

For questions, or for information about registration, contact Ella Peek.